TTOO T2 BIOSYSTEMS INC

T2 Biosystems Announces 2018 Second Quarter Financial and Operational Results Release and Conference Call Date

T2 Biosystems Announces 2018 Second Quarter Financial and Operational Results Release and Conference Call Date

LEXINGTON, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that it will release its 2018 second quarter financial and operational results after the market closes on Thursday, August 2, 2018. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Thursday, August 2, 2018 to discuss the financial results and other business developments.

Interested parties may access the live call via telephone by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784 (International). To listen to the live call via T2 Biosystems' website, go to , in the Investors/Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call, also in the Investors/Events & Presentations section of the website.

About T2 Biosystems:

T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, and T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including products for the detection of additional species and antibiotic resistance markers of sepsis pathogens, and tests for Lyme disease. For more information, please visit .

Media Contact:

Gina Kent, Vault Communications

610-455-2763

Investor Contact:

Matthew Clawson, W2O Group



949-370-8500

EN
20/07/2018

Underlying

TTOOT2 BIOSYSTEMS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on T2 BIOSYSTEMS INC

 PRESS RELEASE
Free
TTOO T2 BIOSYSTEMS I...

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 ...

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results Achieved record fourth quarter and full-year 2024 sepsis product revenues LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 and Recent Commercial Highlights (unaudited) Achieved record product revenues of $2...

January 7, 2025 1 EN
 PRESS RELEASE
Free
TTOO T2 BIOSYSTEMS I...

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing Euro...

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor Multiple instrument sale demonstrates growing market penetration of T2 Biosystems’ sepsis tests LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four T2Dx® Instruments to its European (EU) distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market penetration. The multiple instrume...

December 18, 2024 1 EN
 PRESS RELEASE
Free
TTOO T2 BIOSYSTEMS I...

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test ...

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally Milestone demonstrates the growing customer adoption of the Company’s proprietary technology LEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has surpassed the shipment of 250,000 sepsis tests, marking a significant milestone that underscores the growing customer adoption of the Company’s direct-from-whole-blood technology. A meta-analysis of 14 c...

December 17, 2024 1 EN
 PRESS RELEASE
Free
TTOO T2 BIOSYSTEMS I...

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supp...

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven health care performance improvement company in the United States, has been extended through March 31, 2026. The products covered under the contract with Vizient include the T2Dx® Instrument, ...

December 16, 2024 1 EN
 PRESS RELEASE
Free
TTOO T2 BIOSYSTEMS I...

T2 Biosystems Announces Plans to License its Proprietary Technology to...

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream LEXINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to license its proprietary technology to expand its leadership in di...

December 9, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch